All In Biotech

Drug Trial Radar · NCT03056209

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study

Last checked: Nov 19, 2026Latest source record: Apr 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jun 26, 2017

Primary completion

Apr 16, 2018

Study completion Apr 16, 2018

Sponsor

Lead sponsor
Yungjin Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this First In Human study is to investigate the safety and tolerability of KL1333 after a single oral dose and to investigate the pharmacokinetic characteristics of KL1333 after a single oral dose.

Conditions

  • MELAS Syndrome
  • Mitochondrial Respiratory Chain Deficiencies

Interventions

  • KL1333 25 mgDrug

    oral administration, single dose, 25 mg 1 tab

  • KL1333 50 mgDrug

    oral administration, single dose, 25 mg 2 tabs

  • KL1333 100 mgDrug

    oral administration, single dose, 100 mg 1 tab

  • KL1333 200 mgDrug

    oral administration, single dose, 100 mg 2 tabs

  • KL1333 400 mgDrug

    oral administration, single dose, 100 mg 4 tabs

  • KL1333 600 mgDrug

    oral administration, single dose, 100 mg 6 tabs

  • KL1333 800 mgDrug

    oral administration, single dose, 100 mg 8 tabs

  • PlaceboDrug

    oral administration, placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of reported adverse eventsTime frame: from day 1 to day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, Jongno-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.